Want to see DMRA full AI Analyst Report?
DMRA Stock Chart & Stats
$28.82
$0.76(2.64%)
At close: 4:00 PM EDT
$28.82
$0.76(2.64%)
Day’s Range― - ―
52-Week Range$2.45 - $38.33
Previous CloseN/A
Volume313.81K
Average Volume (3M)793.64K
Market Cap
$1.87B
Enterprise Value$1.18K
Total Cash (Recent Filing)$540.51M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Oct 30, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-122.42
Shares Outstanding61,735,520
10 Day Avg. Volume469,145
30 Day Avg. Volume793,645
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.13
Price to Sales (P/S)0.00
P/FCF Ratio-4.66
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$43.33Price Target Upside50.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong SolvencyVery low debt and near-zero debt-to-equity provide durable solvency and financial flexibility for a pre-revenue biotech. This structural strength lowers short-term default risk, supports continued R&D spending, and makes external financings less likely to trigger covenant stress.
Reduced Cash Burn TrendA materially smaller operating cash outflow in 2025 signals improving cash discipline or completion of higher-cost activities. Over the next few months this trend can extend runway, lower near-term financing needs, and improve the company's ability to advance programs before needing fresh capital.
Experienced Internal CFO AppointmentPromoting an internal CFO with public biotech and audit experience reduces transition risk and strengthens financial governance. Durable benefits include improved reporting, informed capital markets engagement, and steadier execution through the post-acquisition and regulatory reporting phases.
Bears Say
No Revenue And Widening Net LossesA pre-revenue profile with sharply expanding net losses is a durable fundamental risk: ongoing negative economics force reliance on capital markets, compress time to value, and raise execution pressure on R&D programs. Large losses make sustained profitability a distant prospect absent product revenue.
Persistent Negative Cash GenerationConsistent negative operating and free cash flow implies structural dependence on external financing to fund operations. Even with a smaller 2025 outflow, the company lacks internally generated cash, constraining strategic flexibility and increasing dilution risk until revenues or sustained positive cash flow emerge.
Equity Swings And Dilution RiskMaterial swings in equity indicate recurring financings or accounting changes that create dilution and capital-structure uncertainty. This is a persistent investor risk: future raises may dilute existing holders, complicate long-term returns, and limit attractiveness to long-horizon institutional investors.
Damora Therapeutics News
DMRA FAQ
What was Damora Therapeutics, Inc.’s price range in the past 12 months?
Damora Therapeutics, Inc. lowest stock price was $2.45 and its highest was $38.33 in the past 12 months.
What is Damora Therapeutics, Inc.’s market cap?
Damora Therapeutics, Inc.’s market cap is $1.87B.
When is Damora Therapeutics, Inc.’s upcoming earnings report date?
Damora Therapeutics, Inc.’s upcoming earnings report date is Oct 30, 2026 which is in 65 days.
How were Damora Therapeutics, Inc.’s earnings last quarter?
Damora Therapeutics, Inc. released its earnings results on Aug 10, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.414 by $0.024.
Is Damora Therapeutics, Inc. overvalued?
According to Wall Street analysts Damora Therapeutics, Inc.’s price is currently Undervalued.
Does Damora Therapeutics, Inc. pay dividends?
Damora Therapeutics, Inc. does not currently pay dividends.
What is Damora Therapeutics, Inc.’s EPS estimate?
Damora Therapeutics, Inc.’s EPS estimate is -0.48.
How many shares outstanding does Damora Therapeutics, Inc. have?
Damora Therapeutics, Inc. has 61,735,520 shares outstanding.
What happened to Damora Therapeutics, Inc.’s price movement after its last earnings report?
Damora Therapeutics, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.414. Following the earnings report the stock price went up 2.776%.
Which hedge fund is a major shareholder of Damora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Damora Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.33 (50.36% Upside)
$43.33 (50.36% Upside)
Blogger Sentiment
Bullish
DMRA Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 499.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
685.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3870.75%
Trailing 12-Months
Company Description
Damora Therapeutics, Inc.
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
DMRA Stock 12 Month Forecast
Average Price Target
$43.33
▲(50.36% Upside)
Technical Analysis
Iovance Biotherapeutics
―
AnaptysBio
―
Zymeworks
―
Stoke Therapeutics
―
Generate Biomedicines, Inc.
―
Ownership Overview
15.90% Insiders
10.69% Mutual Funds
― Other Institutional Investors
67.46% Public Companies and
Individual Investors